PXD101 is a histone deacetylase (HDAC) inhibitor being co-developed by CuraGen and TopoTarget for the treatment of solid and hematologic cancers. It is currently in a phase II clinical trial for the treatment of advanced multiple myeloma.
Under the cooperative R&D agreement (CRADA), the Division of Cancer Treatment and Diagnosis (DCTD), the National Cancer Institute (NCI), and TopoTarget will collaborate to conduct preclinical and non-clinical studies on PXD101 in order to better understand the anti-tumor activity of PXD101 and to provide supporting information for clinical trials of the therapy.
An additional goal will be to select the best next-generation of HDAC inhibitors to be developed as potential drug candidates from TopoTarget’s library of HDAC inhibitors, including compounds exhibiting HDAC subtype selectivity.
Under the license and collaboration agreement between CuraGen and TopoTarget, CuraGen has an exclusive option to select additional HDAC compounds from TopoTarget’s library for clinical development, including those identified under the CRADA with the DCTD.
“We are very pleased that the NCI and TopoTarget have signed a CRADA for the preclinical evaluation of PXD101, and future HDAC inhibitors, as the data generated will help guide and support the clinical trials being conducted by CuraGen,” stated Timothy Shannon, executive vice president of R&D and chief medical officer at CuraGen.